It has been found that single-chain variable fragments antibodies in the cerebrospinal fluid of MS patients is immunoreactive to GAPDH, and the anti-GAPDH immunoglobulin G inhibits the glycolytic activity of GAPDH [8, 11]. Here, GAPDH is linked to myeloid sarcoma.